Programmed cell death involves a complex and interrelated cascade of cysteine proteases termed caspases that are synthesized as inactive zymogens, which are proteolytically processed to active enzymes. Caspase-8 is an initiator caspase that becomes activated when Fas death receptor-Fas ligand (FasL) coupling on the cell surface leads to coalescence of a "death complex" perpetuating the programmed cell death cascade. In this study, brain tissue samples removed from adult patients during the surgical management of severe intracranial hypertension after traumatic brain injury (TBI; n=17) were compared with postmortem control brain tissue samples (n=6). Caspase-8 mRNA was measured by semiquantitative reverse transcription and polymerase chain reaction, and caspase-8 protein was examined by Western blot and immunocytochemistry. Fas and FasL were also examined using Western blot. Caspase-8 mRNA and protein were increased in TBI patients vs. controls, and caspase-8 protein was predominately expressed in neurons. Proteolysis of caspase-8 to 20-kDa fragments was seen only in TBI patients. Fas was also increased after TBI vs. control and was associated with relative levels of caspase-8, supporting formation of a death complex. These data identify additional steps in the programmed cell death cascade involving Fas death receptors and caspase-8 after TBI in humans.
ligand (FasL), and TNF and TNF-related apoptosis-inducing ligand (TRAIL) (11) . Trimerization of death receptors upon cross-linking recruits pro-caspase-8 in the case of Fas and pro-caspase-2 and -10 in the case of TNFR1. This facilitates interaction between the intracellular death domain (DD) and DD containing adaptor molecules, Fas-associated receptor with death domain (FADD), TNF-associated receptor with death domain (TRADD), and Daxx within the cytoplasm, which in turn engages pro-caspase-2, -8 or -10 through interaction of the amino terminal death effector domain (DED). This death-inducing signaling complex (DISC) brings zymogen molecules into proximity, leading to auto-activation of caspase-8, with subsequent activation of caspase-3 (12) . Active caspase-8 has also been shown to cleave the Bcl-2 family member Bid, permitting its carboxy-terminal end to translocate to the outer mitochondrial membrane causing release of cytochrome c (13) and thus, propagation of the intrinsic pathway. The extrinsic pathway can also be triggered by loss of cell survival signals (14) .
There is growing evidence that the extrinsic pathway of programmed cell death contributes to neuronal and glial cell death in experimental TBI. Expression of Fas and FasL is up-regulated (15) , and caspase-8 transcription is increased and caspase-8 processing is seen in the injured cortex after TBI in rats (8) . Furthermore, DISC formation has been reported after TBI in mice and humans (16) . In the current study, we sought to further characterize the extrinsic programmed cell death cascade in human head injury, by examining brain tissue samples from adult patients after severe TBI for caspase-8 mRNA and protein, as well as Fas and FasL.
MATERIALS AND METHODS

Human brain tissue samples
This protocol was approved by the Institutional Review Board at the University of Pittsburgh. Informed consent was obtained from the legal next of kin for each patient, or approval was granted for existing tissue specimens. Patients in the study were admitted to the University of Pittsburgh Medical Center between August 1995 and January 2000. Brain tissue samples were obtained from patients who underwent a decompressive craniectomy as part of the management of life-threatening intracranial hypertension after TBI, clinical or radiographic evidence of cerebral herniation or impending cerebral herniation, or significant mass effect. The samples were collected after surgical resection of the injured area of brain and were residual tissue that would otherwise have been discarded. Samples were from injured temporal (n=14) or frontal (n=2) lobe cortex or cerebellum (n=1). Tissue was frozen and stored at -70°C until it used for analysis. Control samples were frozen postmortem brain specimens obtained from patients who died of causes not related to central nervous system (CNS) trauma. Samples were from temporal lobe cortex and were originally collected between April and October 1996.
RNA isolation and reverse transcriptase-polymerase chain reactin (RT-PCR)
Total cellular RNA was extracted from samples using TRIZOL reagent (Life Technologies, Gaithersburg, MD), and the concentration was determined using a spectrophotometer. Total RNA 1 (µg) from each sample was reverse transcribed with 200 U of Superscript II RT (Invitrogen, Carlsbad, CA) for 50 min at 42°C primed with 0.5 µg of random hexamer at the conditions recommended by the manufacturer. Reverse transcription products were then digested with RNaseH at 37°C for 30 min to remove the RNA template from the cDNA:RNA hybrid molecule and stored at -20°C until ready for digoxigenin labeling PCR amplification. cDNA samples (1 µl) were subjected to PCR amplification, using primers specific for human caspase-8 (5′-GCAAAAGCACGGGAGAAAG-3′ and 5′-GGATACAGCAGATGAAGCAG-3′) and β-actin (Ambion, Austin, TX). Reaction was performed in a Robocycler Gradient 96 PCR system (Stratagene, La Jolla, CA) in 0.2 ml thin-walled reaction tubes, using a Plantinum Taq PCRx kit (Life Technologies). Reagents were assembled in a final volume of 50 µl, and final concentration of reagents were as follows: 1 µl of first strand cDNA, 1 µM of each primer, 1× PCR amplification buffer, 2.5 mM MgSO4, 1× PCR DIG labeling mix (Roche Molecular Biochemicals, Indianapolis, IN), and RNase free water to volume. Samples were initially denatured at 94°C for 3 min and 2 U of Taq DNA polymerase were then added. PCR conditions were first optimized to determine the number of cycles for reaching the exponential phase of amplification. Optimal thermocycling parameters were 1 min at 94°C, 1 min annealing at 55°C, and 1 min extension at 72°C repeated for 30 cycles with a final extension step at 72°C for 10 min. PCR products were then separated on a 1.2% agarose gel and transferred onto nylon membrane (Schleicher and Shuell, Keene, NH) overnight in 20× SSC. After air drying and UV cross-linking, the membrane was blocked at room temperature for 1 h in 3% blocking reagent in 1× maleic acid buffer (Roche Molecular Biochemicals) and incubated for 30 min at room temperature with alkaline phosphate conjugated anti-digoxigenin at a concentration of 1:10,000 in 1% blocking reagent. A CDP-Star chemiluminescent reagent (NEN Life Science, Boston, MA) was applied before exposing the membrane to X-ray film. The densitometry of each band was determined using an image analysis system (Kodak 440CF, Rochester, NY).
Western blot analysis
Brain tissue samples were sonicated in lysis buffer containing 0.1 M NaCl, 0.01 M Tris, 0.1 mM EDTA, and the following protease inhibitors: 2 µg/ml chymostatin, 2 µg/ml leupeptin, 2 µg/ml pepstatin, and 100 µg/ml phenylmethylsulphonyl fluoride (PMSF). Lysates were centrifuged at 10,000g for 30 min at 4°C, and protein concentration was determined using bicinchoninic acid (Pierce, Rockford, IL). Protein samples (50 µg) were then boiled in loading buffer for 5 min, chilled on ice, electrophoretically separated on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel, and transferred onto PVDF membrane (Bio-Rad, Hercules CA). The primary antibodies included a rabbit polyclonal anti-caspase-8 antibody generated against the epitope corresponding to amino acids 217-350 of human caspase-8 (SC-7890, Santa Cruz Biotechnology, Santa Cruz, CA) reactive with both the 20-kD cleaved fragment (p20) and precursor form of human caspase-8, a mouse monoclonal anti-human Fas antibody (F22120, BD Transduction Laboratories, San Diego, CA), and a mouse monoclonal anti-human FasL antibody (F37720, BD Transduction Laboratories). After blocking overnight in 5% nonfat milk in phosphate-buffered saline (PBS), the membrane was incubated with anti-caspase-8 antibody diluted 1:200 in blocking reagent at room temperature for 1 h, and washed in 0.1% Tween20 in PBS (PBST) three times for 10 min each. Secondary antibody (horseradish peroxidase [HRP]-conjugated goat anti-rabbit IgG; SC-2004, Santa Cruz Biotechology) was applied at 1:2000 dilution for 1 h. The blot was washed in PBST, developed using a chemiluminescence detection system (NEN Life Science), and exposed to X-ray film. The relative optical density (R.O.D.) of detected peptides was semiquantified using a Kodak imaging system.
Immunocytochemistry
To determine cell type expressing caspase-8 in human brain after TBI, we performed immunocytochemistry on samples from a subset of TBI patients (1, 5, 6, 8, and 11) . These specimens were immersion-fixed in 2% paraformaldehyde, cryoprotected in sucrose, and then snap frozen in 2-methylbutane in liquid nitrogen. Because control tissue processed in this manner is not available, samples from control patients were not assayed. Specimens were cut in to 10-µM sections, using a cryostat, and mounted on glass slides. Slides were washed three times with PBS containing 0.5% bovine serum albumin and 0.15% glycine (buffer A). Nonspecific activity was blocked with 5% normal goat serum in buffer A. Brain sections were then incubated overnight at room temperature in a 1:100 dilution of caspase-8 antibody and a 1:500 dilution of the neuron-specific NeuN (Chemicon, Temecula, CA) or a 1:500 dilution of the astrocytespecific GFAP (Chemicon, Temecula, CA). Sections were then washed three times in buffer A and incubated for 1 h in a 1:200 dilution of strep-avidin conjugated Alexa 488 (Molecular Probes, Eugene, OR) and a 1:3000 dilution of anti-rabbit cy3.18 immunoconjugate (Jackson Immunochemicals, West Grove, PA). Sections were then washed three times in buffer A. Immunofluorescence was visualized using excitation/emission wavelengths of 488/520 (green) and 550/565 (red) nm, and images were collected using an Olympus light microscope equipped for epifluorescent illumination. In sections from each specimen, the primary antibody was omitted to assess for nonspecific binding of the secondary antibody.
Data analysis
Data are presented as mean ±SD or median (range) where appropriate. Differences in relative protein and mRNA levels between TBI and control groups were determined using a t test or a Mann-Whitney rank sum test if the data violated the assumptions of normality and/or equal variance. Comparisons of relative protein levels and clinical outcome variables within the TBI group were made using a t test or a Mann-Whitney rank sum test or Spearman-rank correlation for nonparametric data. P≤0.05 was considered significant.
RESULTS
Clinical variables for control patients are shown in Table 1 . The average age of the control group was 52 ± 22 years. The average postmortem time was 10.5 ± 5.7 h. Clinical variables for TBI patients are shown in Table 2 . The average age of the TBI group was 40 ± 17 years. The median admission Glasgow Coma Scale (GCS) score was 6 (3-15). The median latest available Glasgow Outcome Scale (GOS) score was 3 (1-5).
Caspase-8 mRNA after TBI
As shown in Figure 1 , the ratio of caspase-8/actin mRNA is increased in TBI patients compared with controls (10.6 [0-62.2] vs. 0 [0-4.7], respectively; P<0.05). Predicted PCR products of 211 and 294 bp for caspase-8 and actin, respectively, were detected. The uneven actin RT-PCR signal suggests differential preservation of mRNA in the samples. This is not surprising given that mRNA is rapidly degraded by RNases; however, the presence of a strong actin PCR signal in control patients suggests that the increase in caspase-8 mRNA in TBI patients is not merely a reflection of complete mRNA digestion in the control samples, confirmed by denatured agarose gel electrophoresis (data not shown). Samples without detectable RNA were not further processed for RT-PCR (patients 3, 6, 13, and 14). Two RT-PCR products were often detected for both actin and caspase-8. This could represent the presence of a double-strand PCR product that would have delayed migration through a nondenaturing agarose gel or truncated mRNA either as a result of storage conditions or alternative splicing.
Caspase-8, Fas, and FasL after TBI
Western blot analysis detected the ∼48-kD precursor form of caspase-8 (pro-caspase-8) in both control brain tissue samples as well as in those of TBI patients (Fig. 2) . The relative abundance of pro-caspase-8 was increased 1.5-fold in TBI patients compared with controls (P<0.05; Fig. 2B and Table 3 ). Proteolytic processing of caspase-8 was seen in 15/16 TBI patients but was only seen in 1/6 control patients. Peptides ranged from ∼20-40 kD. The antibody used for these studies was generated against an epitope within the p20 fragment. The p20 fragment was detected in the majority of TBI patients but not in controls (P<0.01; Fig. 2B and Table 3 ). Caspase-8 levels positively correlated with caspase-8/actin mRNA levels (p20, r s =0.564, P=0.018; p48, r s =0.436, P=0.078), supporting induction of caspase-8 (Fig. 4A) .
Because caspase-8, Fas, and FasL are components of the DISC, relative protein levels of Fas and FasL were also determined using Western blot. The relative abundance of Fas was increased 7.5-fold in TBI patients compared with controls (P<0.02; Fig. 2C and Table 3 ). In contrast, the relative abundance of FasL did not differ between TBI patients and controls (P=0.98; Fig. 2D and Table 3 ). Consistent with DISC formation, relative Fas levels were associated with relative levels of both pro-caspase-8 (r s =0.576, P=0.015) and the p20 cleaved fragment of caspase-8 (r s =0.703, P=0.001); both the TBI and control patients were included in this analysis (Fig. 3B) .
Relative levels of caspase-8 (both p48 and p20), Fas, and FasL were compared with the clinical variables of age, gender, initial GCS, latest GOS, survival, time of resection post-TBI, and whether or not the patient received therapeutic hypothermia as part of the clinical management. Relative levels of Fas were increased by 71% in TBI patients that died vs. those that survived (P=0.05; Table 3 ). Relative levels of Fas were also positively associated with increasing patient age (r s =0.707, P=0.006). Unexpectedly, the p20 cleaved fragment of caspase-8 was increased by 122% in the hypothermic vs. normothermic treatment groups (P=0.02; Table 3 ). There was no association between caspase-8, Fas, or FasL and any of the other clinical variables analyzed.
Neuronal expression of caspase-8 after TBI
Multilabel immunocytochemical analysis using neuronal and glial specific markers demonstrated that the majority of cells with increased caspase-8 immunoreactivity were neurons (Fig. 4) . Pericontusional areas without frank necrosis were examined from the TBI patients (1, 5, 6, 8, and 11) . Sections from patients 1 (Fig. 4D-F) and 8 (Fig. 4A-C) are shown and are representative of all sections examined, where cellular caspase-8 immunoreactivity was seen almost exclusively in NeuN-positive cells in gray matter and was not detected in GFAP-positive cells. Cellular caspase-8 labeling was not seen in sections incubated without primary antibody (data not shown).
DISCUSSION
The novel findings of this study include the following: a) Caspase-8 mRNA is increased in injured brain; b) caspase-8 protein is increased and proteolytically processed in injured brain, an event important for activation of the enzyme (17); c) caspase-8 mRNA levels correlate with protein levels; d) Fas, but not FasL, is increased in injured brain; e) Fas levels are associated with pro-caspase-8, the p20 cleaved fragment of caspase-8, increasing patient age, and death after TBI; and f) caspase-8 appears to be expressed predominately in neurons after TBI in humans. These data demonstrate the involvement of the death receptor, or extrinsic, pathway of programmed cell death involving Fas and caspase-8 in human brain after TBI.
Experimental models have established that the death receptor pathway of programmed cell death is operative in mammalian brain after TBI (15, 16, 18) . After controlled cortical impact injury in rats, increases in Fas and FasL in neurons and astrocytes with morphological changes consistent with programmed cell death is seen (15) . In the present study, an increase in Fas, but not FasL, was seen in injured human brain. The latter pattern is also seen in mice after controlled cortical impact (16) , perhaps implying species differences in the composition of the DISC after TBI. The capacity for TBI to initiate formation of the DISC is now evident in both mice and in patients (16) . Further downstream, caspase-8 proteolysis occurs after both fluid percussion injury (18) and controlled cortical impact in rats, and is localized to neurons, astrocytes, and oligodendrocytes (8) . DISC formation and activation of caspase-8 could lead to subsequent proteolysis and activation of caspase-3, culminating in programmed cell death, an event that has been well documented in multiple models of experimental TBI (4) (5) (6) (7) (18) (19) (20) . In addition to FasFasL/FADD/caspase-8, there is a role for TNF-TNFRI/TRADD/caspase-2 and -10 in death receptor-mediated sequelae after TBI in rodents (21-23) and humans (24, 25) .
The results of this study confirm that similar to experimental models, TBI can initiate multiple programmed cell death pathways in human brain. Neuronal cell death with apoptotic phenotypes has been reported in multiple studies (1, 3, 26) . Evidence for participation of the mitochondrial, or intrinsic, pathway includes reports showing alterations in bcl-2 family proteins in injured brain after trauma in both adult (1, 26, 27) and pediatric (2) patients. In terms of the extrinsic pathway, Qiu et al. (16) demonstrated DISC formation in injured brain from five patients with severe TBI. Other evidence includes the finding that cerebrospinal fluid levels of soluble FasL are increased and positively associated with intracranial pressure after TBI, implying a relationship between Fas and cerebral edema (28). These and the present study showing induction and proteolysis of caspase-8 and increases in brain tissue Fas levels in 17 patients with severe TBI clearly demonstrate the participation of the death receptor, or extrinsic, pathway of programmed cell death after TBI. Activation of caspase-3, positioned at the confluence of the two pathways, has also been reported after TBI in humans (1, 29) .
Is activation of the death receptor pathway after TBI beneficial, detrimental, both, or neither after TBI? Studies in using transgenic mice suggest that the presence of TNF is detrimental early after TBI related to acute edema formation but may be necessary later after TBI as part of the regenerative response (23). In experimental models of ischemia (30) , epilepsy (13) , and neurodegenerative diseases (31) , the extrinsic pathway is thought to participate in neuronal cell death. In humans, after TBI, activation of the Fas death receptor pathway appears primarily detrimental, as CSF levels of soluble FasL correlate with increasing intracranial pressure (28) and early CSF levels of soluble Fas correlate with CSF neuron-specific enolase, a biochemical marker of neuronal cell death (32) . Consistent with these findings, in the present study, injured brain tissue levels of Fas were increased in patients that died compared with those that survived.
Like the intrinsic or mitochondrial programmed cell death pathway, activation of the extrinsic pathway is important for normal development and cell turnover, particularly in inflammatory cells (11) . Therefore, a homeostatic role for Fas and caspase-8 after TBI, similar to that observed for TNF, cannot be ruled out. In mammalian brain, Fas is essential for normal embryologic development, with expression diminishing after birth (33) . The finding in the present study that brain tissue levels of Fas are positively associated with patient age suggests that Fas reactivation may occur more rapidly with increasing age. An alternative possibility is that elderly patients had a greater severity of injury, although there was no association between Fas and initial GCS.
This clinical study has limitations. First, normal human brain samples to serve as experimental controls are simply unavailable. Second, there were primary differences in handling of tissues from patient biopsies compared with postmortem controls such as the time of sampling and the region of brain sampled. Some degradation of RNA in particular, but also protein, is inevitable. For this reason, caspase-8 mRNA was indexed to actin mRNA, and patient samples in which mRNA was completely degraded were not evaluated by RT-PCR. Because pro-caspase-8 was detectable and because there was no evidence of proteolysis in control patients and relative levels of FasL were similar between control and TBI patients, it appears that comparisons of relative protein levels between these two groups can be made.
In conclusion, these data demonstrate that induction, up-regulation, and proteolysis of caspase-8 occurs in human brain after trauma and that relative caspase-8 levels are associated with levels of Fas. An association between relative Fas levels and patient death suggests that the participation of the extrinsic programmed cell death pathway after TBI may be detrimental, but further investigation in both experimental models and in humans is necessary. 
